Wall Street Fundamentals Releases New In-Depth Stock Reports on AVNR, CLDX, RTRX and TGTX


Follow this company

Companies Mentioned

NASDAQ:AVNR / NASDAQ:CLDX / NASDAQ:RTRX / NASDAQ:TGTX
04/14/2014 [ACCESSWIRE]

The Biotech Industry’s recent slide continued Friday as investors continued to shift their portfolios towards safer assets as we enter earnings season. On Friday, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) declined 2.90 percent, down 15.44 percent in the past month, while the SPDR S&P Biotech ETF (NYSEARCA: XBI) fell 4.0 percent, down 20.95 over the same period. "There’s still a continual rotation out of the high-flying momentum stocks of 2013 into more value-driven opportunities," said Stifel Nicolaus portfolio manager Chad Morganlander. "This will continue in the coming weeks as investors look for consistency in earnings. You have concerns about high valuations and flat revenue growth, which is a perfect cocktail for a sector rotation out of growth and into value."

Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) shares traded in the range of $3.28 to $3.69 Friday before settling to close at $3.29, a decrease of 9.37 percent. The stock appears to be facing some resistance at the $3.36 and $3.45 levels with some support at $3.13 and $2.92. Shares of Avanir Pharmaceuticals have fallen approximately 17.0 percent in the past month.

More information on Avanir Pharmaceuticals and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/AVNR

Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares traded in the range of $13.93 to $15.54 Friday before settling to close at $14.02, a decrease of 10.24 percent. The stock appears to be facing some resistance at the $15.54, $21.90 and $23.87 levels. Shares of Celldex Therapeutics have fallen approximately 41.0 percent in the past month.

More information on Celldex Therapeutics and access to the free equity report can be found at:      
www.WallStreetFundamentals.com/CLDX

Retrophin Inc. (NASDAQ: RTRX) shares traded in the range of $15.32 to $18.08 Friday before settling to close at $15.36, a decrease of 15.84 percent. The stock appears to be facing some resistance at the $17.02 and $18.08 levels with some support at $14.64 and $13.50. Shares of Retrophin have fallen approximately 13.0 percent in the past month.

More information on Retrophin and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/RTRX

TG Therapeutics, Inc. (NASDAQ: TGTX) shares traded in the range of $5.38 to $6.28 Friday before settling to close at $5.50, a decrease of 10.42 percent. The stock appears to be facing some resistance at the $5.50 and $6.12 levels with some support at $4.74 and $4.53. Shares of TG Therapeutics have fallen approximately 27.0 percent in the past month.

More information on TG Therapeutics and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/TGTX

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com

COMMENTS

Leave a comment...
 * 

Your Name
 *